Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free TENX Stock Alerts

Tenax Therapeutics (TENX) Competitors

Tenax Therapeutics logo
$10.77 -0.18 (-1.64%)
Closing price 04:00 PM Eastern
Extended Trading
$10.79 +0.02 (+0.19%)
As of 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

TENX vs. SEPN, AVBP, COAG, HROW, and WVE

Should you buy Tenax Therapeutics stock or one of its competitors? MarketBeat compares Tenax Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tenax Therapeutics include Septerna (SEPN), ArriVent BioPharma (AVBP), Hemab Therapeutics (COAG), Harrow (HROW), and WAVE Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry.

How does Tenax Therapeutics compare to Septerna?

Septerna (NASDAQ:SEPN) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Septerna has a beta of 2.39, suggesting that its share price is 139% more volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

Septerna has higher revenue and earnings than Tenax Therapeutics. Septerna is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Septerna$45.95M29.97-$48.88M-$0.81N/A
Tenax TherapeuticsN/AN/A-$52.60M-$1.40N/A

Tenax Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Tenax Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Septerna-49.88% -12.72% -8.87%
Tenax Therapeutics N/A -56.32%-53.12%

1.7% of Tenax Therapeutics shares are owned by institutional investors. 4.3% of Septerna shares are owned by company insiders. Comparatively, 3.1% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Septerna had 3 more articles in the media than Tenax Therapeutics. MarketBeat recorded 4 mentions for Septerna and 1 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 1.87 beat Septerna's score of 0.55 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Septerna Positive
Tenax Therapeutics Very Positive

Septerna currently has a consensus price target of $43.13, indicating a potential upside of 41.16%. Tenax Therapeutics has a consensus price target of $29.67, indicating a potential upside of 175.46%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tenax Therapeutics is more favorable than Septerna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Septerna
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80
Tenax Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.83

Summary

Septerna beats Tenax Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Tenax Therapeutics compare to ArriVent BioPharma?

Tenax Therapeutics (NASDAQ:TENX) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

ArriVent BioPharma is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tenax TherapeuticsN/AN/A-$52.60M-$1.40N/A
ArriVent BioPharmaN/AN/A-$166.31M-$3.47N/A

Tenax Therapeutics has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

ArriVent BioPharma's return on equity of -48.98% beat Tenax Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tenax TherapeuticsN/A -56.32% -53.12%
ArriVent BioPharma N/A -48.98%-45.44%

Tenax Therapeutics presently has a consensus price target of $29.67, indicating a potential upside of 175.46%. ArriVent BioPharma has a consensus price target of $43.38, indicating a potential upside of 45.65%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Tenax Therapeutics is more favorable than ArriVent BioPharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tenax Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.83
ArriVent BioPharma
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82

In the previous week, Tenax Therapeutics and Tenax Therapeutics both had 1 articles in the media. Tenax Therapeutics' average media sentiment score of 1.87 equaled ArriVent BioPharma'saverage media sentiment score.

Company Overall Sentiment
Tenax Therapeutics Very Positive
ArriVent BioPharma Very Positive

1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 3.1% of Tenax Therapeutics shares are owned by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

ArriVent BioPharma beats Tenax Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Tenax Therapeutics compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

1.7% of Tenax Therapeutics shares are held by institutional investors. 3.1% of Tenax Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Hemab Therapeutics' return on equity of 0.00% beat Tenax Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemab TherapeuticsN/A N/A N/A
Tenax Therapeutics N/A -56.32%-53.12%

Hemab Therapeutics presently has a consensus target price of $41.75, suggesting a potential upside of 59.53%. Tenax Therapeutics has a consensus target price of $29.67, suggesting a potential upside of 175.46%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenax Therapeutics is more favorable than Hemab Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hemab Therapeutics
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Tenax Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.83

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemab TherapeuticsN/AN/AN/AN/AN/A
Tenax TherapeuticsN/AN/A-$52.60M-$1.40N/A

In the previous week, Hemab Therapeutics had 4 more articles in the media than Tenax Therapeutics. MarketBeat recorded 5 mentions for Hemab Therapeutics and 1 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 1.87 beat Hemab Therapeutics' score of 0.61 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Hemab Therapeutics Positive
Tenax Therapeutics Very Positive

Summary

Tenax Therapeutics beats Hemab Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Tenax Therapeutics compare to Harrow?

Tenax Therapeutics (NASDAQ:TENX) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Tenax Therapeutics has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Tenax Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tenax TherapeuticsN/A -56.32% -53.12%
Harrow -5.57%19.59%2.26%

1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 3.1% of Tenax Therapeutics shares are owned by company insiders. Comparatively, 12.8% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Tenax Therapeutics has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Harrow has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market.

Harrow has higher revenue and earnings than Tenax Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tenax TherapeuticsN/AN/A-$52.60M-$1.40N/A
Harrow$272.30M4.56-$5.14M-$0.41N/A

In the previous week, Harrow had 3 more articles in the media than Tenax Therapeutics. MarketBeat recorded 4 mentions for Harrow and 1 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 1.87 beat Harrow's score of 0.81 indicating that Tenax Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Tenax Therapeutics Very Positive
Harrow Positive

Tenax Therapeutics presently has a consensus target price of $29.67, indicating a potential upside of 175.46%. Harrow has a consensus target price of $69.43, indicating a potential upside of 108.37%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Tenax Therapeutics is more favorable than Harrow.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tenax Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.83
Harrow
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64

Summary

Harrow beats Tenax Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Tenax Therapeutics compare to WAVE Life Sciences?

WAVE Life Sciences (NASDAQ:WVE) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

WAVE Life Sciences currently has a consensus target price of $27.25, suggesting a potential upside of 373.09%. Tenax Therapeutics has a consensus target price of $29.67, suggesting a potential upside of 175.46%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe WAVE Life Sciences is more favorable than Tenax Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
WAVE Life Sciences
1 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.87
Tenax Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.83

WAVE Life Sciences has a beta of -1.33, indicating that its share price is 233% less volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

Tenax Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -255.70%. Tenax Therapeutics' return on equity of -56.32% beat WAVE Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
WAVE Life Sciences-255.70% -56.76% -42.80%
Tenax Therapeutics N/A -56.32%-53.12%

In the previous week, WAVE Life Sciences had 4 more articles in the media than Tenax Therapeutics. MarketBeat recorded 5 mentions for WAVE Life Sciences and 1 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 1.87 beat WAVE Life Sciences' score of 0.32 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
WAVE Life Sciences Neutral
Tenax Therapeutics Very Positive

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by insiders. Comparatively, 3.1% of Tenax Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Tenax Therapeutics has lower revenue, but higher earnings than WAVE Life Sciences. Tenax Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
WAVE Life Sciences$42.73M25.94-$204.38M-$1.06N/A
Tenax TherapeuticsN/AN/A-$52.60M-$1.40N/A

Summary

WAVE Life Sciences beats Tenax Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Tenax Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TENX vs. The Competition

Export
MetricTenax TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$290.45M$3.24B$6.47B$12.54B
Dividend YieldN/A2.38%2.69%5.22%
P/E Ratio-7.6917.7822.3924.18
Price / SalesN/A315.63520.79112.26
Price / CashN/A111.6441.3457.13
Price / Book1.036.639.846.72
Net Income-$52.60M$24.20M$3.57B$337.19M
7 Day Performance-9.34%-3.24%-1.16%0.48%
1 Month Performance-15.73%0.53%3.85%5.07%
1 Year Performance82.85%47.24%27.40%34.25%

Tenax Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TENX
Tenax Therapeutics
3.705 of 5 stars		$10.77
-1.6%		$29.67
+175.5%		+80.1%$290.45MN/AN/A9
SEPN
Septerna
2.3312 of 5 stars		$30.65
+8.1%		$43.13
+40.7%		+201.5%$1.28B$45.95MN/AN/A
AVBP
ArriVent BioPharma
2.5007 of 5 stars		$27.94
+4.5%		$43.13
+54.3%		+36.0%$1.24BN/AN/A40
COAG
Hemab Therapeutics
4.8047 of 5 stars		$27.84
+7.5%		$41.75
+50.0%		N/A$1.23BN/AN/A72
HROW
Harrow
4.45 of 5 stars		$34.17
+3.5%		$69.43
+103.2%		+9.6%$1.23B$272.30MN/A180

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TENX) was last updated on 6/3/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel